A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : NNRTI

Search Conditions:
Search Keyword : NNRTI
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: NNRTI
Appearance Frequency: 1439 time(s)
Long forms: 16

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
non-nucleoside reverse transcriptase inhibitor
(1282 times)
Acquired Immunodeficiency Syndrome
(435 times)
PI (399 times)
ART (306 times)
NRTI (252 times)
1994 Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and chimeric enzymes of human immunodeficiency viruses types 1 and 2 by two novel non-nucleoside inhibitors.
nonnucleoside RT inhibitor
(78 times)
Virology
(17 times)
RT (63 times)
HIV-1 (22 times)
NRTI (17 times)
1995 Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
non-NRTI
(44 times)
Acquired Immunodeficiency Syndrome
(13 times)
NRTI (31 times)
PI (20 times)
ART (12 times)
1999 Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients.
non-nucleoside RTI
(14 times)
Acquired Immunodeficiency Syndrome
(4 times)
NRTI (7 times)
RT (6 times)
ART (4 times)
2000 Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
nonnucleoside inhibitor of HIV-1 reverse transcriptase
(6 times)
Drug Therapy
(1 time)
AIDS (1 time)
CNS (1 time)
HAART (1 time)
1999 Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.
next-generation nonnucleoside reverse transcriptase inhibitor
(5 times)
Drug Therapy
(2 times)
HIV-1 (1 time)
NNRTIs (1 time)
PK (1 time)
2009 Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Nevirapine is the first member of a new therapeutic class
(1 time)
Medicine
(1 time)
HIV (1 time)
NRTIs (1 time)
1999 [Nevirapine (Viramune): a new HIV inhibitor].
Nevirapine, an antiviral drug, is a potent reverse transcriptase inhibitor
(1 time)
Biomedical Engineering
(1 time)
HIV-1 (1 time)
2018 Improving the solubility of nevirapine using A hydrotropy and mixed hydrotropy based solid dispersion approach.
new class of antiretroviral agents
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
--- 1999 HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
10  NNRTI linked to appropriate spacers
(1 time)
Chemistry
(1 time)
HIV-1 (1 time)
RT (1 time)
1999 Imidazo[1,5-b]pyridazine-d4T conjugates: synthesis and anti-human immunodeficiency virus evaluation.
11  NNRTI resistance tended to increase over time
(1 time)
Medicine
(1 time)
PI (1 time)
2010 Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort.
12  non-nucleoside reverse transcriptase inhibitor-associated mutations
(1 time)
Medicine
(1 time)
ART (1 time)
CI (1 time)
HIV-1 (1 time)
2011 Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009.
13  Non-Nucleoside-Transcriptase Inhibitor
(1 time)
Pharmacology
(1 time)
HAART (1 time)
PI (1 time)
2011 Mitochondrial toxicity in HAART: an overview of in vitro evidence.
14  non-reverse transcriptase inhibitor
(1 time)
Medicine
(1 time)
MSM (1 time)
NRTI (1 time)
PDR (1 time)
2019 National survey of pre-treatment HIV drug resistance in Cuban patients.
15  nonnucleoside human immunodeficiency virus-1 reverse transcriptase inhibitors
(1 time)
Biochemistry
(1 time)
FEB (1 time)
MM (1 time)
PB/GS (1 time)
2004 Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
16  nonnucleoside reverse transcriptase inhibitor-based regimen
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
DRM (1 time)
PMTCT (1 time)
2017 High Prevalence of HIV Drug Resistance Among Newly Diagnosed Infants Aged <18 Months: Results From a Nationwide Surveillance in Nigeria.